PL2830658T3 - Stabilne formulacje środków wiążących lgG4 - Google Patents

Stabilne formulacje środków wiążących lgG4

Info

Publication number
PL2830658T3
PL2830658T3 PL13714505T PL13714505T PL2830658T3 PL 2830658 T3 PL2830658 T3 PL 2830658T3 PL 13714505 T PL13714505 T PL 13714505T PL 13714505 T PL13714505 T PL 13714505T PL 2830658 T3 PL2830658 T3 PL 2830658T3
Authority
PL
Poland
Prior art keywords
binding agent
agent formulations
igg4 binding
stable igg4
stable
Prior art date
Application number
PL13714505T
Other languages
English (en)
Inventor
Dirk Usener
Ahmed YOUSSEF
Annika Hagendorf
Martina KIRSCH
Sabrina RUGGEBERG
Julia Schnieders
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of PL2830658T3 publication Critical patent/PL2830658T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL13714505T 2012-03-26 2013-03-26 Stabilne formulacje środków wiążących lgG4 PL2830658T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261615539P 2012-03-26 2012-03-26
FR1351013 2013-02-06
EP13714505.8A EP2830658B1 (en) 2012-03-26 2013-03-26 Stable igg4 binding agent formulations
PCT/US2013/033881 WO2013148686A2 (en) 2012-03-26 2013-03-26 Stable igg4 binding agent formulations

Publications (1)

Publication Number Publication Date
PL2830658T3 true PL2830658T3 (pl) 2019-02-28

Family

ID=49261390

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13714505T PL2830658T3 (pl) 2012-03-26 2013-03-26 Stabilne formulacje środków wiążących lgG4

Country Status (7)

Country Link
EP (3) EP2830658B1 (pl)
JP (1) JP6265970B2 (pl)
BR (2) BR112014023952B1 (pl)
CA (3) CA2868401C (pl)
PL (1) PL2830658T3 (pl)
RU (1) RU2644214C2 (pl)
WO (1) WO2013148686A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017025000A2 (pt) 2015-05-22 2018-08-07 The Bot Of The Leland Stanford Junior University tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
TWI760345B (zh) * 2016-07-05 2022-04-11 法商賽諾菲公司 抗體調配物
SG11201900043TA (en) 2016-07-05 2019-02-27 Sanofi Sa Antibody formulations
RU2755065C2 (ru) * 2016-11-11 2021-09-13 Байер Акциенгезельшафт Способ отбора образцов из потока текучей среды для отслеживания загрязняющей примеси в непрерывном режиме
DK3541366T3 (da) * 2016-11-21 2025-03-03 Amylyx Pharmaceuticals Inc Bufferformuleringer af exendin (9-39)
GB201701194D0 (en) * 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
CN112057419B (zh) * 2017-03-01 2023-08-22 免疫医疗有限公司 单克隆抗体的配制品
TW202228779A (zh) * 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP4271412A4 (en) * 2020-12-30 2024-12-04 Ammax Bio, Inc Extended local release of antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
MXPA04007924A (es) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Formulaciones en solucion que contienen anticuerpo.
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US20060148009A1 (en) 2004-10-12 2006-07-06 Xencor, Inc. Prediction and assessment of immunogenicity
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US9084777B2 (en) * 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN101426817B (zh) * 2006-04-21 2013-07-10 诺华有限公司 拮抗性抗-cd40抗体药物组合物
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
CA2671968A1 (en) * 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
HUE037489T2 (hu) * 2007-08-29 2018-08-28 Sanofi Sa Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
JP6024025B2 (ja) * 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮

Also Published As

Publication number Publication date
EP2830658A2 (en) 2015-02-04
CA3123252C (en) 2023-08-22
WO2013148686A3 (en) 2013-11-28
CA3204402A1 (en) 2013-10-03
WO2013148686A2 (en) 2013-10-03
JP6265970B2 (ja) 2018-01-24
EP2830658B1 (en) 2018-10-10
JP2015514090A (ja) 2015-05-18
EP4527855A2 (en) 2025-03-26
RU2644214C2 (ru) 2018-02-08
CA2868401C (en) 2021-08-24
BR112014023952A2 (pt) 2017-07-18
CA2868401A1 (en) 2013-10-03
BR122019026701B1 (pt) 2023-01-24
RU2014142990A (ru) 2016-05-20
BR112014023952B1 (pt) 2023-01-24
EP3431104A1 (en) 2019-01-23
EP4527855A3 (en) 2025-06-11
CA3123252A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
IL286348A (en) Pharmaceutical preparations that include allopregnanolone
PL2830658T3 (pl) Stabilne formulacje środków wiążących lgG4
SG11201404577XA (en) Bactericidal agent composition
ZA201502013B (en) Nicotine composition
ZA201500212B (en) Progesterone formulations
IL235322A0 (en) Pesticides
IL235585B (en) Substances that bind to ha, preparations containing them and their uses
GB2502339B (en) Solid cosmetic composition
PL2582761T3 (pl) Wodne kompozycje środków wiążących
GB201200707D0 (en) Composition
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
SG11201406278PA (en) Pesticidal composition
AP3681A (en) Modified release formulations for oprozomib
SI2830589T1 (sl) Nikotinski pripravek
EP2878295A4 (en) COMPOSITION
SG11201500544SA (en) Composition for agent for external use
ZA201503755B (en) Herbicide composition
GB2507522B (en) Solid cosmetic composition
EP2856873A4 (en) HERBICIDE COMPOSITION
GB201210530D0 (en) Extended release formulations
GB201105162D0 (en) Improved deodorant formulations
IL236357A0 (en) The composition of misoprostol
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
PT2830658T (pt) Formulações de agente de ligação igg4 estável
GB201206178D0 (en) Formulations